FBP1 induced by β‐elemene enhances the sensitivity of gefitinib in lung cancer

β-Elemene Restrains PTEN mRNA Degradation to Restrain the Growth of Lung Cancer Cells via METTL3-Mediated N6 Methyladenosine Modification

(2022) Yuxu Feng et al.   Journal of Oncology

Age-period-cohort analysis of lung cancer mortality in China and Australia from 1990 to 2019

(2022) Ning Wang et al.   Scientific Reports

Targeting nicotinamide N-methyltransferase overcomes resistance to EGFR-TKI in non-small cell lung cancer cells

(2022) Jun Wang et al.   Cell Death Discovery

Fructose‐1,6‐bisphosphatase aggravates oxidative stress‐induced apoptosis in asthma by suppressing the Nrf2 pathway

(2021) Jiapeng Hu et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation

(2021) Jinyun Dong et al.   JOURNAL OF MEDICINAL CHEMISTRY

FBP1 regulates proliferation, metastasis, and chemoresistance by participating in C-MYC/STAT3 signaling axis in ovarian cancer

(2021) Haoran Li et al.   ONCOGENE

Targeting STAT3 signaling overcomes gefitinib resistance in non-small cell lung cancer

(2021) Zhe Liu et al.   Cell Death & Disease

High expression of FBP1 and LDHB in fibroadenomas and invasive breast cancers

(2021) Ika Yustisia et al.   Breast Disease

FBP1 enhances the radiosensitivity by suppressing glycolysis via the FBXW7/mTOR axis in nasopharyngeal carcinoma cells

(2021) Pengfei Zhang et al.   LIFE SCIENCES

Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer

(2021) Dan Yan et al.   Cancers

FBP1 loss disrupts liver metabolism and promotes tumorigenesis through a hepatic stellate cell senescence secretome

(2020) Fuming Li et al.   NATURE CELL BIOLOGY

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

(2020) Yi-Long Wu et al.   Lancet Respiratory Medicine

CELF6 modulates triple-negative breast cancer progression by regulating the stability of FBP1 mRNA

(2020) Xiaowei Yang et al.   BREAST CANCER RESEARCH AND TREATMENT

β-Elemene Enhances radiosensitivity in non-small-cell lung cancer by inhibiting epithelial–mesenchymal transition and cancer-stewm cell traits via Prx-1/NF-kB/iNOS signaling pathway

(2020) Kun Zou et al.   Aging-US

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

miRNA 146a promotes chemotherapy resistance in lung cancer cells by targeting DNA damage inducible transcript 3 (CHOP)

(2018) Wenfeng Tan et al.   CANCER LETTERS

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR -mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

(2018) Wen-Zhao Zhong et al.   LANCET ONCOLOGY

Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase

(2018) Roger W. Hunter et al.   NATURE MEDICINE

β-Elemene Synergizes With Gefitinib to Inhibit Stem-Like Phenotypes and Progression of Lung Cancer via Down-Regulating EZH2

(2018) Haibo Cheng et al.   Frontiers in Pharmacology

Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures

(2017) Dae Ho Lee   PHARMACOLOGY & THERAPEUTICS

Interplay of DNA methyltransferase 1 and EZH2 through inactivation of Stat3 contributes to β-elemene-inhibited growth of nasopharyngeal carcinoma cells

(2017) JingJing Wu et al.   Scientific Reports

β-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1

(2016) Xiaoqiang Li et al.   Scientific Reports

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

(2015) Jean-Charles Soria et al.   LANCET ONCOLOGY

Loss of FBP1 by Snail-Mediated Repression Provides Metabolic Advantages in Basal-like Breast Cancer

(2013) Chenfang Dong et al.   CANCER CELL

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease

(2013) Kadoaki Ohashi et al.   JOURNAL OF CLINICAL ONCOLOGY

Reversion of Multidrug Resistance in a Chemoresistant Human Breast Cancer Cell Line by ß-Elemene

(2012) Hong-Bin Xu et al.   PHARMACOLOGY

Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M

(2012) Ho-June Lee et al.   Cancer Discovery

P21 (waf1/cip1) is required for non-small cell lung cancer sensitive to Gefitinib treatment

(2011) Yi-Fan Zhao et al.   BIOMEDICINE & PHARMACOTHERAPY

Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib

(2011) Vince D. Cataldo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fructose-1,6-Bisphosphatase Regulates Glucose-Stimulated Insulin Secretion of Mouse Pancreatic β-Cells

(2010) Ye Zhang et al.   ENDOCRINOLOGY

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-tumor effect of β-elemene in glioblastoma cells depends on p38 MAPK activation

(2008) Yi-Qun Yao et al.   CANCER LETTERS